This Article Free upon publication Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rosenbaum, D. S. Search for Related Content PubMed PubMed Citation Articles by Rosenbaum, D. S.

(Circulation. 2008;118:2015-2018.)
© 2008 American Heart Association, Inc.

Editorial

T-Wave Alternans in the Sudden Cardiac Death in Heart Failure Trial Population

Signal or Noise?

David S. Rosenbaum, MD

From the Heart and Vascular Center, MetroHealth Campus, Case Western Reserve University, Cleveland, Ohio.

Correspondence to David S. Rosenbaum, MD, Professor of Medicine, Biomedical Engineering, Physiology, and Biophysics, Director, Heart and Vascular Center, Metro Health Campus, Case Western Reserve University, 2500 MetroHealth Dr, Hamman 330, Cleveland, OH 44109-1998. E-mail drosenbaum@metrohealth.org

Key Words: Editorials • death, sudden • heart failure • cardioversion • prevention

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
Although the cardiovascular death rate has fallen in recent years, the proportion of cardiovascular deaths attributed to sudden cardiac death (SCD) is on the rise. SCD is usually caused by ventricular tachyarrhythmias resulting from complex electroanatomic changes that follow myocardial injury, most often associated with coronary artery disease. Ventricular tachyarrhythmia episodes and the factors responsible for triggering them are poorly understood, usually occur without warning or provocation, and result almost invariably in death. Therefore, efforts aimed at predicting and preventing SCD have emerged as the major paradigm for addressing this significant unresolved public health dilemma.

Article p 2022

Two major randomized clinical trials demonstrated that implantable cardioverter defibrillators (ICDs) reduce mortality in patients selected for primary prevention of SCD on the basis of reduced left ventricular ejection fraction (LVEF) alone.^1,2 However, recent studies have questioned whether LVEF used in isolation from other disease markers is sufficient to guide SCD prevention.³ Although ICDs are highly effective in aborting SCD from ventricular fibrillation, only 1 of 15 patients satisfying current guidelines for prophylactic ICDs on the basis of an LVEF <0.35 benefit from ICDs. Moreover, current guidelines fail to address the largest source of SCD victims (ie, patients with LVEF >0.35). Also, we have yet to ascertain how to incorporate estimates of competitive risk from nonarrhythmic and noncardiac mortality into the decision to implant ICDs. Finally, current paradigms that focus on assessing risk at 1 time point do not account for dynamic time-varying modulation of SCD substrates that occur in response to . . . [Full Text of this Article]

This article has been cited by other articles:

				G. M. De Ferrari and R. L. Verrier Letter by De Ferrari and Verrier Regarding Article, "Role of Microvolt T-Wave Alternans in Assessment of Arrhythmia Vulnerability Among Patients With Heart Failure and Systolic Dysfunction: Primary Results From the T-Wave Alternans Sudden Cardiac Death in Heart Failure Trial Substudy" Circulation, July 21, 2009; 120(3): e20 - e20. [Full Text] [PDF]

				J.-P. Couderc Measurement and regulation of cardiac ventricular repolarization: from the QT interval to repolarization morphology Phil Trans R Soc A, April 13, 2009; 367(1892): 1283 - 1299. [Abstract] [Full Text] [PDF]